IVD PRODUCT | EndoPredict®

Breast Cancer Precision Medicine

EndoPredict®

The second generation of multi-gene for prognostic prediction of breast cancer

Fifteen years of prognostic validation data provided more accurate recurrence risk assessment
Recommended by domestic diagnosis and treatment guidelines
Recommended by international authoritative medical guidelines
MYRAID GENETICS exclusive strategic partnership
Exclusive introduction by Shuwen Biotech.

PREFERRED POPULATION

When other clinical indicators are low risk and there are only a few high-risk factors;
When elderly patients may be intolerant to chemotherapy;
When younger patients were planning to have children or concerned about long term prognosis;
When patients intended to be exempted from chemotherapy;

CLINICAL VALUE

To assess 10-year distant recurrence risk for patients receiving Standard endocrine therapy.

Individualized chemotherapy benefit prediction:

To predict the benefit of chemotherapy combined endocrine therapy in reducing 10-year recurrence risk.

Prolonged endocrinotherapy decision:

For patients without recurrence after 5 years of endocrine therapy only, the risk of distant recurrence in 5-15 years should be detected to provide basis to decide prolonging endocrine therapy

Recommended by authoritative guidelines globally